With the explosion of biological data now available as a direct result of genome sequencing initiatives, use of commercial gene synthesis and pre-designed synthetic biology tools is becoming increasingly popular. We wanted to understand how molecular cloners feel about using synthetic biology tools as replacements for in-house methods such as cloning. So, in December 2013, we polled users of…read more >
We set out to understand, at a top level, which life science suppliers are recognized in the industry for having the most flexible pricing options, for reagents and for instruments. The questions posed to North American, European and Chinese audiences were:
Q. Which life science reagent supplier has the most flexible pricing options?
Q. Which life science instrument supplier…read more >
We set out to understand, at a top level, which life science suppliers are recognized in the industry for having the most memorable advertising, for reagents and for instruments. The questions posed to North American, European and Chinese audiences were:
Q. Which life science reagent supplier has the most memorable advertising?
Q. Which life science instrument supplier has the…read more >
When was the last time your company produced a printed catalog? You might want to consider the effectiveness of a printed catalog for certain regions such as in China. In Apr 2013, we polled Chinese cell culture researchers regarding what catalogs they used in the last month to purchase life science research products and whether it was in print…read more >
China remains an attractive market for life science tools suppliers capable of taking advantage…read more >
In February 2013 we polled our panel of fluorescent imaging reagent users regarding their anticipated laboratory budget. Data reveals that commercial users anticipate a slight increase compared to academic users. As shown in the table, 24.1% of commercial users of fluorescent imaging reagents expect their budget to increase over the next 12 months, vs. 17.6% of academic users (a…read more >
If you thought cell therapy had suffered too many setbacks in recent years and was stuck in neutral – think again. In a recent Percepta poll of 250 randomly selected life science researchers working in biotechnology and pharmaceutical companies more than 20% are involved in projects focused on allogeneic or autologous cell therapy and/or regenerative medicine. Even more surprising…read more >